RU2758632C2 - Антитела против edb и конъюгаты антитело-лекарственное средство - Google Patents

Антитела против edb и конъюгаты антитело-лекарственное средство Download PDF

Info

Publication number
RU2758632C2
RU2758632C2 RU2019111303A RU2019111303A RU2758632C2 RU 2758632 C2 RU2758632 C2 RU 2758632C2 RU 2019111303 A RU2019111303 A RU 2019111303A RU 2019111303 A RU2019111303 A RU 2019111303A RU 2758632 C2 RU2758632 C2 RU 2758632C2
Authority
RU
Russia
Prior art keywords
edb
antibody
cancer
seq
heavy chain
Prior art date
Application number
RU2019111303A
Other languages
English (en)
Russian (ru)
Other versions
RU2019111303A (ru
RU2019111303A3 (enExample
Inventor
Андреа Тереза ХУПЕР
Кимберли Энн МАРКЕТТ
Чакрапани Субраманиам
Ханс-Петер Гербер
Чад Майкл МЭЙ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2019111303A publication Critical patent/RU2019111303A/ru
Publication of RU2019111303A3 publication Critical patent/RU2019111303A3/ru
Application granted granted Critical
Publication of RU2758632C2 publication Critical patent/RU2758632C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2019111303A 2016-10-17 2017-10-03 Антитела против edb и конъюгаты антитело-лекарственное средство RU2758632C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
US62/409,081 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Publications (3)

Publication Number Publication Date
RU2019111303A RU2019111303A (ru) 2020-11-17
RU2019111303A3 RU2019111303A3 (enExample) 2020-11-17
RU2758632C2 true RU2758632C2 (ru) 2021-11-01

Family

ID=60117722

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019111303A RU2758632C2 (ru) 2016-10-17 2017-10-03 Антитела против edb и конъюгаты антитело-лекарственное средство

Country Status (22)

Country Link
US (5) US20190269791A1 (enExample)
EP (3) EP3525828B1 (enExample)
JP (4) JP7039577B2 (enExample)
KR (1) KR102338660B1 (enExample)
CN (2) CN110087691B (enExample)
AU (3) AU2017344440B2 (enExample)
CA (1) CA3040423A1 (enExample)
DK (1) DK3525828T3 (enExample)
ES (1) ES3007557T3 (enExample)
FI (1) FI3525828T3 (enExample)
HR (1) HRP20250056T1 (enExample)
HU (1) HUE070615T2 (enExample)
IL (2) IL310865A (enExample)
LT (1) LT3525828T (enExample)
MX (2) MX2019004434A (enExample)
PL (1) PL3525828T3 (enExample)
PT (1) PT3525828T (enExample)
RS (1) RS66524B1 (enExample)
RU (1) RU2758632C2 (enExample)
SG (1) SG11201903400WA (enExample)
SI (1) SI3525828T1 (enExample)
WO (1) WO2018073680A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP7514836B2 (ja) * 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
US20240252662A1 (en) * 2021-05-20 2024-08-01 Case Western Reserve University Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
EP4716555A1 (en) * 2023-07-10 2026-04-01 Wuxi Xdc Singapore Private Limited Antibody-drug conjugates and production thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
WO2010093395A1 (en) * 2009-02-13 2010-08-19 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2014124316A2 (en) * 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CA2937731A1 (en) * 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
WO2015162563A1 (en) * 2014-04-25 2015-10-29 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5952329A (en) 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
PT1257297E (pt) * 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
EP2239274A1 (en) * 2002-01-03 2010-10-13 Bayer Schering Pharma AG New methods for diagnosis and treatment of tumours
JP2005534283A (ja) 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
WO2004012735A2 (en) * 2002-07-31 2004-02-12 Schering Ag New effector conjugates, process for their production and their pharmaceutical use
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2624667C (en) 2005-10-05 2018-01-09 Commonwealth Scientific And Industrial Research Organisation Silk proteins containing coiled coil region
EP1842553A1 (en) * 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
KR101436222B1 (ko) * 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
WO2012041451A1 (en) 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
CN113698488A (zh) * 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
TWI703160B (zh) * 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
WO2010093395A1 (en) * 2009-02-13 2010-08-19 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2014124316A2 (en) * 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CA2937731A1 (en) * 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
WO2015162563A1 (en) * 2014-04-25 2015-10-29 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Epub 2011 Mar 8. WEI C., et al., Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.Anal Chem. 2016 May 3;88(9):4979-86. doi: 10.1021/acs.analchem.6b00976. Epub 2016 Apr 21. *
PALUMBO A., et al., A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.Br J Cancer. 2011 Mar 29;104(7):1106-15. doi: 10.1038/bjc.2011.78. *
PALUMBO A., et al., A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.Br J Cancer. 2011 Mar 29;104(7):1106-15. doi: 10.1038/bjc.2011.78. Epub 2011 Mar 8. WEI C., et al., Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.Anal Chem. 2016 May 3;88(9):4979-86. doi: 10.1021/acs.analchem.6b00976. Epub 2016 Apr 21. *

Also Published As

Publication number Publication date
AU2017344440B2 (en) 2020-07-30
RS66524B1 (sr) 2025-03-31
EP4635516A3 (en) 2026-05-06
AU2020260375A1 (en) 2020-11-19
US20230241235A1 (en) 2023-08-03
HUE070615T2 (hu) 2025-06-28
JP2019534706A (ja) 2019-12-05
EP4635516A2 (en) 2025-10-22
US20190269791A1 (en) 2019-09-05
EP3525828A1 (en) 2019-08-21
CN116251196A (zh) 2023-06-13
JP2022016581A (ja) 2022-01-21
SG11201903400WA (en) 2019-05-30
RU2019111303A (ru) 2020-11-17
LT3525828T (lt) 2025-02-25
US20240156977A1 (en) 2024-05-16
CA3040423A1 (en) 2018-04-26
MX2024003463A (es) 2024-04-03
KR102338660B1 (ko) 2021-12-10
PT3525828T (pt) 2025-01-29
US20240181071A1 (en) 2024-06-06
IL266112A (en) 2019-06-30
KR20190069493A (ko) 2019-06-19
CN110087691B (zh) 2023-02-03
IL310865A (en) 2024-04-01
SI3525828T1 (sl) 2025-04-30
AU2024201216A1 (en) 2024-05-16
MX2019004434A (es) 2019-09-26
US20240261423A1 (en) 2024-08-08
FI3525828T3 (fi) 2025-01-27
JP7039577B2 (ja) 2022-03-22
JP7383682B2 (ja) 2023-11-20
EP4617283A2 (en) 2025-09-17
ES3007557T3 (en) 2025-03-20
HRP20250056T1 (hr) 2025-04-11
IL266112B2 (en) 2024-07-01
IL266112B1 (en) 2024-03-01
CN110087691A (zh) 2019-08-02
EP3525828B1 (en) 2024-12-25
WO2018073680A1 (en) 2018-04-26
US11833216B2 (en) 2023-12-05
JP2025175010A (ja) 2025-11-28
PL3525828T3 (pl) 2025-03-31
BR112019007760A2 (pt) 2019-09-03
RU2019111303A3 (enExample) 2020-11-17
JP2023184697A (ja) 2023-12-28
DK3525828T3 (da) 2025-02-17
AU2020260375B2 (en) 2023-11-30
AU2017344440A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
AU2020260375B2 (en) Anti-EDB antibodies and antibody-drug conjugates
JP6629837B2 (ja) 抗ｐｔｋ７抗体−薬物コンジュゲート
CN109195991B (zh) 对糖基化pd-l1特异的双重功能抗体及其使用方法
US12371507B2 (en) CDCP1 antibodies and antibody drug conjugates
JP2020510435A (ja) 抗ｇｉｔｒ抗体およびその使用方法
HK40131862A (en) Anti-edb antibodies and antibody-drug conjugates
HK40092426A (zh) 抗-edb抗体和抗体-药物缀合物
US20260139067A1 (en) Cdcp1 antibodies and antibody drug conjugates
HK40012788B (en) Anti-edb antibodies and antibody-drug conjugates
WO2025208105A1 (en) Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders
HK40012788A (en) Anti-edb antibodies and antibody-drug conjugates
BR112019007760B1 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica, ácido nucleico, vetor, processo para a produção do conjugado de anticorpofármaco e uso do conjugado de anticorpo-fármaco
BR122024006481A2 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina